Vistagen Therapeutics, Inc. (VTGN): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:08 ET
- Event date
- 2026-11-13
- Accession no.
- 0001628280-26-073824
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Vistagen reports fiscal year 2027 second-quarter results and fasedienol development update
Vistagen reported a $10.7 million net loss for its fiscal year 2027 second quarter ended September 30, 2026, versus $19.4 million a year earlier. It said cash resources should fund operations into 2027, but not for more than a year from the release date. Following FDA feedback, it plans to focus future Phase 3 development of fasedienol on overall treatment of social anxiety disorder.
- Net loss was $10.7 million for the three months ended September 30, 2026, compared with $19.4 million a year earlier.
- R&D expense fell to $6.6 million from $15.9 million for the comparable three-month periods.
- Cash, cash equivalents, and marketable securities were $20.0 million as of September 30, 2026.
- Following FDA feedback, Vistagen plans future Phase 3 development of fasedienol for overall treatment of social anxiety disorder.
earningsproductregulatory
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | vtgn-20261113.htm |
| EX-99.1 | EX-99.1 | vtgn-20261112xex991.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.